Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation
Top Cited Papers
- 1 August 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (15) , 3483-3489
- https://doi.org/10.1200/jco.2001.19.15.3483
Abstract
PURPOSE: To evaluate the efficacy, toxicity, and optimal dose rate of gemcitabine in adult patients with advanced soft tissue sarcomas (STS) by comparing levels of gemcitabine triphosphate (GTP) in...Keywords
This publication has 12 references indexed in Scilit:
- New agents in the treatment of soft-tissue sarcomasExpert Opinion on Investigational Drugs, 2000
- Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomasAnti-Cancer Drugs, 2000
- Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II studyCancer Chemotherapy and Pharmacology, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumorsAnnals of Oncology, 1998
- A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumorsInvestigational New Drugs, 1997
- Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.Journal of Clinical Oncology, 1992
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabineCancer Chemotherapy and Pharmacology, 1991
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989